2025 ACA Winter Conference Orlando_Program Book

historical and current trends in incidence, prevalence and deaths due to HCV infection globally, nationally and in U.S. justice system settings. Risk factors for HCV infection are reviewed. The natural history of untreated HCV is discussed, as are the health variables that impact the rate of HCV liver disease progression. We also present the latest data on the positive impact that direct-acting antiviral medicines has had on the death rates due to HCV in the U.S. Learning Objectives: • Correctly interpret infectious disease data presented as either incidence or prevalence. • Differentiate between the stages of illness caused by HCV infection. • Articulate the disproportionate burden of illness that hepatitis C has on justice system-involved individuals, and the marked positive change in rate of illness that has occurred with the introduction of direct-acting antiviral HCV medications. Moderator: Jennifer G. Clarke , M.D., MPH, Physician Consultant, American Correctional Association, Providence, Rhode Island Speaker 1: John J. Hagan , M.D., FASAM, American Correctional Association, Fort Collins, Colorado Speaker 2: Kathleen F. Maurer , M.D., MPH, M.B.A., American Correctional Association, Westbrook, Connecticut

what the size of this population will likely be in the near future. Then, we will discuss how dementia is diagnosed and how to rule out other conditions which can mimic dementia. Next, we will list the diagnostic tests used to identify dementia and the latest treatment options for the disease. We finish the presentation by examining eight practices currently being implemented to provide better care for inmates with dementia. These practices are (1) early and ongoing screening, (2) specialized services, (3) specialized units, (4) dementia specific programs and activities, (5) adaptation of the incarcerated environment, (6) early release or parole for older prisoners with dementia that are deemed at low risk for reoffending, (7) training younger prisoners, as well as (8) staff to assist older prisoners with dementia. Learning Objectives: • Identify inmates with dementia. • Describe the treatment options available for patients with dementia. • Identify eight practices that are currently being implemented to support better care for prisoners with dementia. Moderator: Clayton Weiss , MPH, Director Office of Health Services, Florida Department of Corrections, Tallahassee, Florida Speaker 1: Danny Martinez , M.D., MPH, Chief of Medical Services, Florida Department of Corrections, Tallahassee, Florida Speaker 2: Jerome Greenfield , M.D., DLFAPA, Deputy Chief Officer — Psychiatry, VitalCore Health Strategies, Topeka, Kansas Speaker 3: Thomas Culbreath , Psy.D., Internship and Residency Training Director, Zephyrhills Correctional Institution, Zephyrhills, Florida ACA Hepatitis C Elimination Program Part 1 — Epidemiology and Natural History of HCV in the Era of Direct Acting Antiviral Medications [CE/CME] Room W230 C Overview: This session presents the ACA Hepatitis C Elimination Program Modules 1 & 2 — Epidemiology and Natural History of HCV. We briefly review the concepts of incidence and prevalence. We then present

WORKSHOPS Friday, Jan. 10 ▼ 2–3:30 p.m.

76 — ACA 2025 Winter Conference | Orlando